Randomized Phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

Larry W. Hertel, G B Boder, Julian S. Kroin et al. · PubMed · 1990 · 683 citations

Medicine, Oncology, Pharmacology +11

Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guérin–Refractory Transitional-Cell Carcinoma of the Bladder

Guido Dalbagni, Paul Russo, Joel Sheinfeld et al. · Journal of Clinical Oncology · 2002 · 261 citations

Medicine, Oncology, Pharmacology +11

Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study

Menachem Laufer, Sakkaraiappan Ramalingam, Mark Schoenberg et al. · Journal of Clinical Oncology · 2003 · 103 citations

Medicine, Oncology, Pharmacology +12

Phase II Study to Investigate the Ablative Efficacy of Intravesical Administration of Gemcitabine in Intermediate-Risk Superficial Bladder Cancer (SBC)

Paolo Gontero, Giovanni Casetta, G. Maso et al. · European Urology · 2004 · 91 citations

Medicine, Oncology, Urology +10

Intravesical Gemcitabine: A Phase 1 and Pharmacokinetic Study

J. Alfred Witjes, Antoine G. van der Heijden, J.L.J. Vriesema et al. · European Urology · 2003 · 47 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12